pan-Pim kinase inhibitors (Amgen)

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug Namepan-Pim kinase inhibitors (Amgen)

Drug Alias NameAM-6826

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionProto-oncogene serine/threonine-protein kinase Pim-1 inhibitorsSerine/threonine-protein kinase pim-2 inhibitorsSerine/threonine-protein kinase pim-3 inhibitors

TargetsSerine/threonine-protein kinase pim-2Serine/threonine-protein kinase pim-3Proto-oncogene serine/threonine-protein kinase Pim-1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAmgen Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A